RH Bophelo Limited Overview
| Item | Detail | Source |
|---|---|---|
| Legal name | RH Bophelo Limited | FY2026 AFS |
| Former name | Newshelf 1388 Proprietary Limited | SENS, 5 Jul 2017 |
| Registration number | 2016/533398/06 | FY2026 AFS |
| Incorporated | 13 December 2016, Republic of South Africa | FY2026 AFS, note 1 |
| Founder | Quinton Zunga (founder, CEO) | TradingView profile; Business Day, Jul 2017 |
| Headquarters / registered office | Unit 12, 1st Floor, 1 Melrose Boulevard, Melrose Arch, Johannesburg, 2076 | FY2026 AFS; SENS 25 Nov 2025 |
| Primary listing | JSE Main Board, 12 July 2017; first listed as a SPAC and now an investment entity under Section 15 of the JSE Listings Requirements | SENS; Profile's Handbook 2025 |
| JSE sector classification | Financials – Closed End Investments | Profile's Handbook 2025 |
| Secondary listing | Rwanda Stock Exchange, by introduction, 1 June 2020 | FY2021 abridged results |
| Tickers | JSE: RHB (vendor alias RHBE; RHB.JO); RSE: RHB | SENS |
| ISIN | ZAE000244737 | SENS |
| CUSIP | Not applicable / not publicly disclosed (FIGI BBG00H416BS4 per TradingView) | TradingView |
| Fiscal year end | Last day of February | AFS |
| Shares in issue | 64,691,298 "A" ordinary shares, plus 1 unlisted "B" restrictive share held by the investment manager | FY2026 AFS, note 13 |
| Employees (holding company) | Not publicly disclosed. The holdco's employee costs were R9.31m in FY2026. | FY2026 AFS |
| Employees (Profile's Handbook) | 742. The scope is not stated and is likely group/portfolio-wide. | Profile's Handbook 2025 Issue 4 |
| Employee 3-year trend | — | — |
| Investment manager | RH Bophelo Management Company (Pty) Ltd (RHBM), external, which holds the "B" share | FY2026 AFS |
| External auditor | Forvis Mazars (formerly Mazars); engagement partner Stephan Adlam CA(SA) | FY2026 AFS |
| JSE sponsor | BSM Sponsors (Pty) Ltd. Previously Deloitte & Touche Sponsor Services; the change was made between Nov 2025 and May 2026. | FY2026 AFS; SENS 30 Jun 2026 |
| RSE sponsor | Faida Securities Rwanda Limited | FY2026 AFS |
| Company secretary | Statucor (Pty) Ltd. In 2021 it was Corporate Vision Consulting. | FY2026 AFS; FY2021 results |
| Transfer secretary | Computershare Investor Services (Pty) Ltd | SENS |
| B-BBEE status | Level 1 | SENS, 27 Jul 2026 |
| Net asset value (NAV), FY2026 | R1,096,831,961; NAV per share 1,695.5 cents | FY2026 AFS |
| Market capitalisation (current) | About R106.7m at 165c/share × 64.69m shares (analyst-derived). TradingView displays R112.56m (see note). | TradingView, Oct 2026 |
| Price / NAV | About 0.10x, a discount of roughly 90% to reported NAV (analyst-derived) | — |
| Website | www.rhbophelo.co.za | SENS |
RH Bophelo is a small, black-owned, Johannesburg-based investment holding company. It allocates permanent capital to South African healthcare and healthcare-adjacent financial services. It listed on the JSE in 2017 as a R500m special purpose acquisition company and later converted into a Section 15 investment entity. It now holds about R1.15bn of unlisted portfolio investments, all measured at fair value. Roughly 78% of that value sits in an "asset-heavy" cluster of independent, mostly peri-urban private hospitals and related property companies: Africa Healthcare, Rondebosch Medical Centre, Medicare, Vryburg, RH Bell and Fauchard. The remaining ~21% sits in an "asset-light" cluster of pharmaceutical distribution (MMed/1-Pharma), radiology (RazoHealth), dialysis (Renal Healthcare Africa), pathology (Ambit/Pelo) and benefits administration (Wesmart). Its stated purpose is affordable care for lower- and middle-income South Africans. The investment case hinges on the gap between a reported NAV of R16.96 per share and a thinly traded share price of about R1.65. That gap is shaped by external management, a concentrated register dominated by the Public Investment Corporation, and Level-3 valuations.
Company's own description (FY2026 AFS, paraphrased)
The company describes itself as an investment entity listed on the JSE and RSE. It seeks returns for shareholders through equity, quasi-equity and equity-related investments in healthcare and financial services. It names the target areas as operational infrastructure, health insurance, private hospital infrastructure, pharmaceuticals, retail and distribution, and healthcare technology.
It executes this mandate through two wholly owned investment-entity subsidiaries:
-
RH Bophelo Operating Company (Pty) Ltd (RHBO), which holds healthcare investments.
-
RH Financial Services (Pty) Ltd (RHFS), which holds healthcare-related financial services investments.
Portfolio management is outsourced under a shareholder-approved management agreement to RH Bophelo Management Company (Pty) Ltd (RHBM). RHBM is not controlled by the company (FY2026 AFS, notes 1 and 4.1).
In FY2026 the company described its strategy as a deliberate move from an "asset-heavy owner and operator" of healthcare facilities to an "asset-light owner and manager of healthcare assets". The aim is to participate in the broader healthcare value chain through partnerships, scalable operating models and new ventures in pharmacy distribution, pathology, radiology and dialysis (FY2026 AFS, Directors' Report, note 9).
Independent characterisation
Economically, RH Bophelo is a listed, externally managed, permanent-capital private equity vehicle. It invests in a concentrated set of unlisted South African healthcare businesses. Several features follow from its accounting status:
-
Revenue model. Under IFRS 10 the company and its two sub-holding companies qualify as investment entities. The company therefore does not consolidate its hospitals or distribution businesses. Its "revenue" is made up of:
-
dividends received from RHBO;
-
interest on shareholder loans (mainly the Notamed/RH Bell property loan) and on cash;
-
fair-value gains or losses on the portfolio, which are unrealised and Level-3. No look-through product, service or subscription revenue mix is published in the AFS. The FY2025 Integrated Annual Report summary on AfricanFinancials (an AI-generated summary, unaudited) states that asset-light businesses contributed 32% of "Group revenues" and were growing at more than 15% a year. The underlying Rand revenue is not disclosed in the sources retrieved.
-
-
Value-chain position. Through its investees the company sits across several parts of the care chain:
-
acute and day-hospital care: St Helena (Welkom), Fochville, Carletonville, Vryburg, Rondebosch, Medicare, RH Bell, Fauchard, and Platinum via Dorama;
-
hospital property ownership: Magnacorp, Notamed, St Helena property;
-
pharmaceutical wholesale/distribution: MMed, now trading as 1-Pharma;
-
diagnostics: RazoHealth radiology and Ambit/Pelo pathology;
-
renal dialysis: Renal Healthcare Africa;
-
nursing education: AHC Nursing College;
-
emergency medical services: Gerijo EMS;
-
medical-scheme/benefits administration: Wesmart. In December 2021 the IFC described the company as owning eight hospitals and managing fourteen more for third parties through a hospital consulting, commissioning and management subsidiary. Whether that management business is still active is not disclosed in the FY2026 AFS.
-
-
Customer types and end-markets. The ultimate payers are medical schemes, insured individuals, self-paying lower- and middle-income patients and, to a degree, the state. At listing in 2017, management said it would serve people who cannot afford private care as currently structured, focusing on small independent hospitals in peri-urban areas (Business Day, July 2017). MMed sells to external pharmacies and to RH-owned pharmacies (FY2024 AFS, note 6.1).
-
Mix of income (analyst-derived from AFS):
Source: FY2024, FY2025 and FY2026 AFS, statements of profit or loss.
Analytical note on the FY2026 dividend. Dividend income rose to R83.69m in FY2026, but only R15.84m was received in cash (FY2026 cash flow statement). Dividends receivable increased by R11.73m, from R4.80m to R16.53m. The remaining ~R56.1m matches the R56.13m of "capital paid – non cash" on the Norsad loan almost exactly (FY2026 AFS, note 15). Our inference, which the company does not state explicitly, is that most of the FY2026 dividend was settled non-cash: the Norsad holding-company debt was discharged and refinanced at investee level (Africa Healthcare). The headline jump in dividend income is therefore largely a transfer of leverage from the holding company down to the portfolio, not an increase in cash yield.
Strategy
Stated corporate strategy (themes from the FY2025 and FY2026 AFS and IAR summaries, paraphrased)
-
Asset-light transition. Move from owning and operating healthcare facilities to owning and managing healthcare assets, optimising capital allocation while keeping strategic influence (FY2026 AFS).
-
Value-chain participation. Grow through partnerships, scalable operating models and new ventures in pharmacy distribution, pathology, radiology and dialysis (FY2024–FY2026 AFS).
-
Service integration and margin. Management says the asset-light strategy lowers input costs, improves operating margins and enables integration across the portfolio (FY2025 and FY2026 Directors' Reports).
-
Affordable access. The founding mission is quality care for lower- to middle-income earners in the gap between public and premium private care (2017 listing; company profile).
-
Digital and AI-enabled care. The FY2025 IAR summary references deployment of AI-powered electronic medical records.
-
NHI positioning. Management supports the NHI and sees potential participation in future state-led contracting frameworks, while acknowledging risks to funding flows and pricing (FY2026 AFS).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Source |
|---|---|---|---|
| Renal Healthcare Africa JV (dialysis) | May 2024 onward | 51% with Renocare SA; R8.3m equity; fair value R21.9m at FY2026 | FY2025–FY2026 AFS |
| RazoHealth radiology rollout | FY2025–FY2026 | 3 practices at FY2025, 4 at FY2026; R6.6m and R2.0m deployed. The IAR summary mentions a 15-centre rollout. | AFS; FY2025 IAR summary |
| 1-Pharma / MMed consolidation of pharmacy operations | FY2025 | 1-Pharma took full operational control of group pharmacy operations; R8m and R5.5m working-capital loans | FY2025 IAR summary; AFS |
| Fauchard support | Oct 2024; Sep 2025 | R1.6m and R0.11m working-capital advances | AFS |
| Capital-structure reset | FY2026 | Norsad R100m facility discharged and refinanced at asset level (Africa Healthcare). Capitec working-capital facility (prime-linked, annual review, R25m RHBO guarantee, R20m cash pledge). FNB R10m overdraft closed. | FY2026 AFS, notes 12 and 15 |
| Office lease renewal | Oct 2025 | Three-year extension (right-of-use asset R3.18m) | FY2026 AFS |
| Board renewal | Jan 2025; Oct 2025 | Mpelwane, Mashau and Ndhlazi appointed; new ARC chair | SENS; AFS |
| Sponsor change | Between Nov 2025 and May 2026 | JSE sponsor moved from Deloitte to BSM Sponsors | AFS; SENS |
| Energy resilience | FY2024 onward | Alternative-energy plan for operating facilities in response to load-shedding | FY2024 AFS |
Cost programmes with targets: None publicly disclosed. The H1 FY2026 results referred generically to "cost containment measures".
Medium-term financial targets / guidance
Capital structure: A target "gearing" ceiling of 30% (FY2026 AFS, note 13).
"B" share hurdle: 10% NAV growth baseline, which is a de-facto performance benchmark for the manager.
Explicit guidance: No NAV, earnings or dividend guidance is published.
Historic ambitions, not current guidance: - At listing the company said it would not pay dividends for at least three years.
-
In 2018 the CEO cited a medium-term R5bn portfolio target.
-
In 2021 the IFC announced a planned US$56m raise. None of these appears in recent filings, and the US$56m raise has not been reported as completed.
Products & Services
RH Bophelo does not sell products itself. Its "portfolio" is its investee companies. Each one is profiled below. Fair values, costs and post-tax WACC come from the FY2026 AFS (note 6) unless stated. Investee revenue, beds, theatres and pricing are not publicly disclosed in the AFS.
Asset-heavy segment
(1) Africa Healthcare (Pty) Ltd ("AHC") — 100%
Description: Owns and operates hospitals. The FY2021 results also mentioned pharmaceutical distribution within AHC.
Facilities: Subsidiaries listed in FY2026 are St Helena Private Hospital and St Helena Hospital (Welkom, Free State), AHC Fochville Hospital (Gauteng), The Fountain Private Hospital, RH Pelo Carletonville Hospital (Gauteng) and CFM. St Helena Hospital, Welkom, appears in third-party medical-scheme network lists (LA Health; Bankmed). The Fountain Private Hospital also appears in the LA Health 2026 network list.
Property: In FY2026 the valuation includes only the St Helena property, at R46m and a 14% capitalisation rate. In FY2025 it included St Helena (R53m at 11%) and Fochville (R11m at 12.5%). Dropping Fochville from the property list in FY2026 is not explained in the sections retrieved.
Valuation: Fair value R383.62m (33% of the portfolio). Cost R122.5m. WACC 19.20%. Share of investee net assets (unaudited) R57.19m.
Income to the company FY2026: R15.68m.
Strategic note: AHC is the largest single asset and, per the FY2026 AFS, the level at which debt was refinanced to align debt with the underlying assets.
Original acquisition: 60% announced November 2017; now 100%.
(2) Rondebosch Medical Centre (Pty) Ltd ("RMC") — 100%
Description: Hospital services in Rondebosch, Cape Town. Includes RMC Pharmacy (100%).
Acquisition: 30% initially (2018, per secondary source), plus 70% in March 2020 for R93.75m. Total cost R143.7m.
Valuation: Fair value R199.47m (17%). WACC 19.53%. Share of net assets negative R386.1m. The company attributes the negative net asset value to the IFRS 16 lease effect (FY2024 AFS, note 6.1), which implies a large lease obligation, probably on the hospital premises.
Valuation history: R224.3m in FY2023, R233.2m in FY2024, R195.1m in FY2025 (-R37.1m) and R199.5m in FY2026 (+R5.0m).
Income FY2026: R0.92m.
Other: In March 2023 the company advanced a R6m working-capital loan, of which R1m was repaid in FY2024. Net receipts from RMC were R1.0m in FY2025 and R0.7m in FY2026.
(3) Medicare Private Hospital — 54% of the operating company (BMC Gilliwie), 50.1% of the property company (Magnacorp 84), held through Megafrack
Description: Hospital services plus investment property. The location is not disclosed in the sources reviewed.
Valuation: Fair value R200.43m (17%). Cost R123.5m. WACC 20.44%. Share of net assets R108.63m. The property value in the valuation is R113.2m at an 11% capitalisation rate.
FY2026 fair value change: -R14.25m.
Restatement: The FY2026 AFS restated the FY2025 property value used in sensitivity disclosures from R211m to R122m to reflect the correct attributable share.
Income: Nil in FY2025 and FY2026, against R12.92m in FY2024.
Covenant: Under the Norsad covenants, Medicare EBITDA had to be at least R20m. It was R48.1m in FY2025 (FY2025 AFS, note 27).
(4) Vryburg Private Hospital (Fezinet t/a Vryburg Private Hospital) — 81% via Vryburg Holding Company
Description: Hospital services in Vryburg, North West. It appears in medical-scheme network lists.
Acquisition: 76% of the HoldCo announced in November 2017; now reported at 81%.
Valuation: Fair value R69.59m (6%). Cost R43.85m. WACC 20.53%. Property R25.92m at 11%.
Income FY2026: R2.46m.
History: Received COVID relief shareholder loans of R7.4m in FY2021. Revalued up by R26.7m in FY2025.
(5) RH Bell Clinic (Pty) Ltd and Notamed (Pty) Ltd (property company) — 100%
Description: Hospital/clinic services. The property sits in Notamed. Location not disclosed.
Valuation: Fair value R37.82m. Property R33m at 10%.
Shareholder loan to Notamed: R55.33m at FY2026, measured at fair value and repayable by March 2028 with no fixed instalments. The rate is 7.75% per the FY2026 AFS; the FY2025 AFS stated 10%, a discrepancy noted here. Interest accrued was R4.33m in FY2026.
Security: First-ranking bond under the former Norsad facility.
(6) Fauchard Day Clinic (Fauchard Tandheelkundige Sentrum) — 100%
Description: Day hospital/clinic. "Tandheelkundige" is Afrikaans for "dental", which suggests a dental/day-surgery origin. Listed in medical-scheme networks at Florida (Roodepoort), Gauteng.
Valuation: Fair value R8.0m (R13.0m in FY2025; R14.0m in FY2024), equal to the property value at an 11.5% capitalisation rate. The operating business is therefore valued at nil.
Recent advances: R0.11m in September 2025; R1.6m in October 2024.
(7) Dorama Investments (Pty) Ltd — 100%
Holdings: AHC Nursing College (nursing education), Platinum Private Hospital and Gerijo EMS (emergency medical services), all 100%.
Valuation: Fair value R2.8m. It was written down to R1 in FY2023/FY2024 and rose to R2.8m in FY2025.
Locations: Not disclosed.
Asset-light segment
(8) MMed Distribution Services (Pty) Ltd / 1-Pharma — 100%
Description: Pharmaceutical distributor with distribution licences across South Africa. Sells to external and RH pharmacies. The FY2025 IAR summary states that 1-Pharma took full operational control of the group's pharmacy operations.
Acquisition: 31 May 2023 for R1.
Funding: R4.8m bridging loan in FY2024; R8m in March 2024 (repaid within FY2025); R5.5m in March 2025.
Valuation: Fair value R167.45m (15%). Revalued from R0 to R158.1m in FY2024, to R185.0m in FY2025, then down to R167.5m in FY2026 (-R23.1m). WACC 20.45%.
Income FY2026: R1.47m.
(9) RazoHealth Radiology (Pty) Ltd — 60% JV with a radiologist
Description: Founded 31 July 2023. Originally a management company for radiology practices. The FY2026 AFS says it "operates" the practices: three were operational at the end of FY2025 and four at the end of FY2026. The FY2025 IAR summary refers to the start of a rollout of 15 diagnostic centres (secondary; unaudited summary).
Capital deployed: R0.13m in FY2024, R3.5m in March 2024, R6.6m in FY2025, R2.0m in FY2026.
Valuation: Fair value R40.82m.
(10) Renal Healthcare Africa (Pty) Ltd — 51% JV with Renocare South Africa (Pty) Ltd
Description: Dialysis services. Founded May 2024 with R8.3m of equity from RHBO.
Valuation: Fair value R21.93m (R19.84m in FY2025).
Related entity: "RHB Renal Care (Pty) Ltd" (74%) is also listed as a related party in FY2025. Its role relative to the JV is not explained.
(11) Ambit Health (Pty) Ltd ("Pelo") — 29% associate
Description: Pathology services. Acquired 1 March 2023 for R1.075m.
Valuation: Fair value R5.90m, down from R13.88m in FY2025 (-R7.98m in FY2026).
(12) Wesmart Financial and Administration Solution (Pty) Ltd — 60% via RHFS
Description: Financial and administration solutions (medical-scheme/benefit administration). In FY2020 it operated a cell-captive arrangement with Genric Insurance, backed by a R3m RH Bophelo guarantee.
Valuation: Fair value R3.0m. Shareholder loans of R0.4m in FY2026, R0.5m in FY2025 and R1.1m in FY2024 have each been written off through fair value.
(13) Locumbase (Pty) Ltd — 10%
Description: Not described in the AFS; the name suggests healthcare locum staffing. Written down from R4.0m in FY2022 to nil in FY2024.
Exited / historical holdings
| Holding | Business | Exit | Source |
|---|---|---|---|
| Genric Insurance Company Ltd (25%, later 30%) | Short-term insurance | Exited FY2023 for R61.5m | FY2021 results; FY2024 AFS |
| Phelang Bonolo Healthcare Procurement & Management (PBHPM) | Healthcare procurement and management | Sold for R14m. Classified held for sale in FY2023, completed in FY2024. R8.2m was received by FY2025 and an ECL of R1.17m was raised. In FY2026 the ECL was reversed and the receivable is nil, implying recovery (inference). | FY2024–FY2026 AFS |
| RH 12J Limited | Section 12J venture capital company | Disposed for R2.1m in 2021 | FY2021 results |
Pricing models and flagship offerings
Investee pricing (hospital tariffs, distribution margins, radiology/dialysis tariffs) is not publicly disclosed. Hospital revenue in South Africa is mainly funded through medical-scheme tariffs negotiated with funders. RH Bophelo's facilities appear in restricted-network lists, for example LA Health's Focus network (St Helena, Vryburg, Fauchard, The Fountain), which suggests network-based contracting with schemes.
Financial Narrative
Basis.
-
Company-only IFRS financial statements of an investment entity. There is no consolidation, so "revenue", "gross profit" and "EBITDA" are not native concepts.
-
"Total income" is used as the revenue proxy: investment income (interest, dividends and fair-value movements) plus other income.
-
"Operating income (EBIT)" is analyst-derived as profit before tax plus finance costs.
-
"EBITDA" is EBIT plus depreciation.
-
Gross profit is not applicable.
-
Only FY2022 balance-sheet items carried as opening balances in the FY2024 AFS comparatives are reported. Equity reconciliation implies FY2022 profit after tax of roughly R49.6m–R53.5m; the range depends on whether the R3.9m "B" dividend was charged to equity.
Income statement: notes and sources
Sources: FY2024 AFS (FY2023 comparatives restated to split employee costs and depreciation), FY2025 AFS, FY2026 AFS.
Margins and growth (analyst-derived)
Gross margin is not applicable to an investment entity. FY2023 margins are not meaningful because total income was negative.
Revenue CAGR. On the total-income basis no meaningful CAGR exists: income swung from negative in FY2023 to a peak in FY2024 and then fell. NAV CAGR FY2022–FY2026 is 4.95% a year (R903.96m to R1,096.83m). NAV per share CAGR over the same period is 4.95% (1,397.3c to 1,695.5c), because the share count was unchanged. From FY2021 to FY2026 the NAV CAGR is 4.89% a year (R864.08m to R1,096.83m).
Supplementary pre-period history (FY2020–FY2021, abridged audited results):
Sources: FY2020 and FY2021 abridged results (SENS).
Balance sheet
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Assets & Liabilities
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Healthcare (RHBO) fair value (ZAR Mn) | 835.67 | 821.16 | 1,086.04 | 1,182.70 | 1,149.96 |
Financial services (RHFS) fair value (ZAR Mn) | 86.33 | 9.29 | 6.98 | 3.00 | 3.00 |
Total financial assets at FVTPL (ZAR Mn) | 922.00 | 830.44 | 1,093.02 | 1,185.70 | 1,152.96 |
Healthcare share of portfolio (%) | 90.64 | 98.88 | 99.36 | 99.75 | 99.74 |
Healthcare fair value change (ZAR Mn) | — | -27.70 | 252.95 | 66.68 | -32.73 |
Financial services fair value change (ZAR Mn) | — | -17.21 | -3.38 | -4.43 | -0.37 |
Healthcare YoY growth in fair value (%) | — | -1.74 | 32.26 | 8.90 | -2.77 |
Segment Assets & Liabilities and Segment Assets & Liabilities (%)
| Segment | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Asset-heavy fair value (ZAR Mn) | 804.67 | 881.38 | 912.10 | 901.72 |
Asset-light fair value (ZAR Mn) | 24.05 | 200.16 | 258.80 | 239.11 |
Unallocated RHBO net assets (ZAR Mn) | 1.73 | 11.49 | 14.80 | 12.13 |
Asset-light share of portfolio (%) | 2.90 | 18.31 | 21.83 | 20.74 |
Asset-heavy fair value change (ZAR Mn) | — | 66.59 | 29.94 | -5.50 |
Asset-light fair value change (ZAR Mn) | — | 183.07 | 34.80 | -27.60 |
Asset-heavy YoY growth (%) | — | 9.53 | 3.49 | -1.14 |
Asset-light YoY growth (%) | — | 732.27 | 29.30 | -7.61 |
Revenue by Segment
| Investee | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Africa Healthcare (ZAR Mn) | 8.08 | 15.19 | 15.68 |
Rondebosch Medical Centre (ZAR Mn) | 1.15 | 0.83 | 0.92 |
Medicare Private Hospital (ZAR Mn) | 12.92 | 0.00 | 0.00 |
MMed Distribution Services (ZAR Mn) | 4.00 | 1.41 | 1.47 |
Vryburg Private Hospital (ZAR Mn) | — | 2.17 | 2.46 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Interest income (ZAR Mn) | 7.43 | 14.68 | 8.04 | 5.71 |
Dividend income (ZAR Mn) | 28.13 | 22.14 | 26.14 | 83.69 |
Fair value gains/(losses) (ZAR Mn) | -55.62 | 243.59 | 72.05 | -36.16 |
Total investment income (ZAR Mn) | -20.07 | 280.42 | 106.23 | 53.24 |
Other income (ZAR Mn) | 4.24 | 4.44 | 5.65 | 0.18 |
Total income – revenue proxy (ZAR Mn) | -15.83 | 284.86 | 111.89 | 53.42 |
Finance costs (ZAR Mn) | 7.03 | 19.98 | 11.47 | 11.05 |
Employee costs (ZAR Mn) | 4.79 | 11.65 | 10.96 | 9.31 |
Management fees to RHBM (ZAR Mn) | 4.07 | 7.42 | 6.79 | 4.51 |
Depreciation (ZAR Mn) | 0.89 | 0.91 | 0.94 | 1.01 |
Expected credit loss charge/(release) (ZAR Mn) | 0.00 | 0.00 | 1.17 | -1.17 |
Other operating expenses (ZAR Mn) | 12.00 | 12.68 | 20.85 | 13.51 |
Total expenses incl. finance costs (ZAR Mn) | 28.78 | 52.64 | 52.17 | 38.22 |
Operating income – EBIT, analyst-derived (ZAR Mn) | -37.58 | 252.19 | 71.18 | 26.24 |
EBITDA, analyst-derived (ZAR Mn) | -36.69 | 253.10 | 72.12 | 27.25 |
Profit/(loss) before tax (ZAR Mn) | -44.61 | 232.21 | 59.71 | 15.20 |
Income tax (charge)/credit (ZAR Mn) | 12.40 | -49.57 | -15.79 | 3.37 |
Net income / total comprehensive income (ZAR Mn) | -32.21 | 182.64 | 43.93 | 18.57 |
Basic & diluted EPS (ZAR cents) | -49.8 | 282.3 | 67.9 | 28.7 |
Headline EPS (ZAR cents) | -49.8 | 282.3 | 67.9 | 28.7 |
Dividend per "A" share declared (ZAR cents) | 0 | 31 | 0 | 0 |
Margin Analysis (%) and Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating (EBIT) margin on total income (%) | — | — | 88.53 | 63.62 | 49.12 |
EBITDA margin on total income (%) | — | — | 88.85 | 64.46 | 51.01 |
Net margin on total income (%) | — | — | 64.12 | 39.26 | 34.76 |
Cash investment income – interest plus dividends (ZAR Mn) | — | 35.55 | 36.82 | 34.18 | 89.40 |
Total expenses / average NAV (%) | — | 3.24 | 5.52 | 4.94 | 3.51 |
NAV growth (%) | 4.62 | -3.56 | 18.65 | 4.25 | 1.72 |
Income Statement and Per-Share Data (FY2020–FY2021)
| Metric | FY2020 | FY2021 |
|---|---|---|
Total investment income (ZAR Mn) | 105.39 | 188.83 |
Fair value gains (ZAR Mn) | 84.06 | 174.48 |
Total expenses (ZAR Mn) | 16.91 | 22.75 |
Profit before tax (ZAR Mn) | 90.46 | 166.52 |
Net income (ZAR Mn) | 69.99 | 131.22 |
Basic EPS (ZAR cents) | 131 | 218 |
NAV (ZAR Mn) | 646.61 | 864.08 |
NAV per share (ZAR cents) | 1,156 | 1,336 |
Total assets (ZAR Mn) | 671.18 | 925.68 |
Cash and equivalents (ZAR Mn) | 120.07 | 34.70 |
Dividend per "A" share declared (ZAR cents) | 0 | 15 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Financial assets at FVTPL (ZAR Mn) | 922.00 | 830.44 | 1,093.02 | 1,185.70 | 1,152.96 |
Loans to related parties at FVTPL (ZAR Mn) | 42.98 | 48.22 | 44.83 | 55.61 | 55.33 |
Cash and cash equivalents, gross (ZAR Mn) | 7.76 | 151.93 | 54.73 | 30.02 | 27.24 |
Total assets (ZAR Mn) | — | 1,033.48 | 1,216.36 | 1,283.18 | 1,258.64 |
Short-term borrowings incl. overdraft (ZAR Mn) | 0.00 | 102.51 | 21.64 | 21.55 | 24.96 |
Long-term borrowings (ZAR Mn) | 0.00 | 0.00 | 50.35 | 49.57 | 0.00 |
Total debt excl. leases (ZAR Mn) | 0.00 | 102.51 | 71.99 | 71.12 | 24.96 |
Lease liabilities (ZAR Mn) | 2.98 | 2.27 | 1.45 | 0.48 | 2.79 |
Net debt excl. leases (ZAR Mn) | -7.76 | -49.42 | 17.26 | 41.10 | -2.28 |
Deferred tax liability (ZAR Mn) | 68.80 | 56.40 | 105.97 | 121.75 | 118.38 |
Total liabilities (ZAR Mn) | — | 161.74 | 182.03 | 204.92 | 161.81 |
Total equity / NAV (ZAR Mn) | 903.96 | 871.74 | 1,034.33 | 1,078.26 | 1,096.83 |
NAV per share (ZAR cents) | 1,397.3 | 1,347.5 | 1,598.9 | 1,666.8 | 1,695.5 |
Goodwill & intangibles (ZAR Mn) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net working capital – net current assets (ZAR Mn) | — | 63.54 | 59.85 | 12.23 | 10.20 |
Shares in issue (millions) | 64.69 | 64.69 | 64.69 | 64.69 | 64.69 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash used in operations (ZAR Mn) | — | -16.85 | -33.24 | -22.96 | -22.06 |
Dividends received in cash (ZAR Mn) | — | 28.13 | 8.14 | 35.35 | 15.84 |
Interest received in cash (ZAR Mn) | — | 3.53 | 11.77 | 2.60 | 1.38 |
Finance costs paid (ZAR Mn) | — | -4.52 | -20.50 | -12.64 | -11.66 |
Net operating cash flow (ZAR Mn) | — | 10.28 | -33.83 | 2.34 | -16.50 |
Capex – PPE (ZAR Mn) | — | 0.05 | 0.08 | 0.05 | 0.00 |
Free cash flow – OCF less capex (ZAR Mn) | — | 10.24 | -33.91 | 2.29 | -16.50 |
Net cash invested in/(realised from) portfolio (ZAR Mn) | — | -34.83 | 12.28 | 25.96 | -4.93 |
Net investing cash flow (ZAR Mn) | — | 34.78 | -12.36 | -26.01 | 4.93 |
Borrowings raised (ZAR Mn) | — | 100.00 | 0.00 | 0.00 | 24.96 |
Borrowings repaid in cash (ZAR Mn) | — | 0.00 | 30.00 | 10.00 | 5.00 |
"A" share dividends paid (ZAR Mn) | 9.70 | 0.00 | 20.05 | 0.00 | 0.00 |
Share buybacks (ZAR Mn) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net financing cash flow (ZAR Mn) | — | 99.10 | -51.01 | -11.04 | 18.78 |
Net change in cash (ZAR Mn) | — | 144.17 | -97.20 | -34.70 | 7.21 |
Margin Analysis (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | — | -3.63 | 19.16 | 4.16 | 1.71 |
ROA on closing total assets (%) | — | -3.12 | 15.02 | 3.42 | 1.48 |
ROIC – EBIT×(1-27%)/(equity+debt) (%) | — | -2.82 | 16.64 | 4.52 | 1.71 |
Current ratio (x) | — | 1.61 | 3.38 | 1.36 | 1.24 |
Debt/equity, interest-bearing (%) | 0.00 | 11.76 | 6.96 | 6.60 | 2.28 |
Total liabilities/equity (%) | — | 18.55 | 17.60 | 19.00 | 14.75 |
Net debt/EBITDA (x) | — | — | 0.07 | 0.57 | -0.08 |
Interest coverage – EBIT/finance costs (x) | — | -5.35 | 12.62 | 6.21 | 2.38 |
Asset turnover – total income/total assets (%) | — | -1.53 | 23.42 | 8.72 | 4.24 |
Results by Region and Revenue by Region (%)
| Region | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
South Africa – total investment income (ZAR Mn) | — | -20.07 | 280.42 | 106.23 | 53.24 |
Rest of Africa incl. Rwanda – total investment income (ZAR Mn) | — | 0.00 | 0.00 | 0.00 | 0.00 |
South Africa – share of portfolio fair value (%) | 100 | 100 | 100 | 100 | 100 |
Province Details
| Province | Facilities |
|---|---|
Free State | St Helena Hospital (Welkom) |
Gauteng | Fochville Hospital; RH Pelo Carletonville Hospital; Fauchard Clinic (Florida, Roodepoort) |
North West | Vryburg Private Hospital |
Western Cape | Rondebosch Medical Centre (Cape Town) |
| — | Medicare, RH Bell, Platinum, The Fountain |
“—” = not publicly disclosed.
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Share price (latest observed, Oct 2026) | 165c | TradingView |
1-year performance | -17.09% | TradingView |
Year-to-date | -17.50% | TradingView |
3-year performance | Not available in the sources retrieved | — |
5-year performance | -67.20% | TradingView |
All-time performance | -83.82%; IPO price R10 (1,000c) | TradingView; SENS |
All-time high / low | 1,160c (28 Sep 2017) / 100c (20 Jul 2023) | TradingView |
Beta (1Y) | 0.60 | TradingView (an earlier snapshot showed -0.55; unreliable given thin trading) |
Liquidity | Very low; frequent "no trades" days. A 2024 independent commentary described the shares as almost untraded. | TradingView |
Capital Markets
| Metric | RH Bophelo |
|---|---|
Market capitalisation | R106.7m (TradingView: R112.56m) |
Enterprise value (market cap + debt R24.96m + leases R2.79m − cash R27.24m) | about R107.2m |
P/E (FY2026 EPS 28.7c) | 5.7x (TradingView: about 6x) |
P/NAV (P/B) | 0.097x |
EV/EBITDA (FY2026 EBITDA R27.25m) | 3.9x |
EV/Sales (total income R53.4m) | 2.0x; on TradingView's R89.6m revenue definition (interest + dividends + other income), 1.2x |
Dividend yield | 0% (no FY2025 or FY2026 dividend) |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
"A" dividend per share declared (ZAR cents) | 15 | — | 0 | 31 | 0 | 0 |
"A" dividends paid in year (ZAR Mn) | 0.00 | 9.70 | 0.00 | 20.05 | 0.00 | 0.00 |
"B" share dividend declared (ZAR Mn) | 0.00 | 3.90 | 0.00 | 0.00 | 0.00 | 0.00 |
Capital Instruments
| Instrument | Amount | Terms |
|---|---|---|
Capitec short-term working-capital facility | R24.96m | Current; prime-linked; repayable monthly; reviewed annually |
Office lease | R2.79m | R1.18m current, R1.62m non-current; runs to about Sep 2028 |
Analyst Conclusions
Management guidance
No quantitative guidance is provided. Qualitatively, management:
-
expects the asset-light strategy to keep supporting value through lower input costs and better margins;
-
regards the diversified, essential nature of its services as supporting resilience in earnings and cash flows;
-
notes continued macro headwinds and NHI uncertainty (FY2026 AFS, Directors' Report).
The going-concern statement covers the 12 months to 28 February 2027.
Consensus expectations
No sell-side coverage or consensus estimates were identified.
Bull case
-
Discount is extreme relative to audited NAV. At about 0.10x NAV, the market implies roughly a 90% haircut to auditor-reviewed carrying values. Africa Healthcare alone is carried at R383.6m, about 3.6x the entire market capitalisation, and paid R15.7m of income in FY2026. Even severe haircuts to carrying values leave large implied upside per share.
-
Holding-company balance sheet de-risked. Norsad has been repaid, holdco net debt is about nil, and the interest-bearing debt/equity ratio is 2.3%. Without the R4.48m early settlement fee, FY2027 finance costs should fall well below FY2026's R11.0m. Combined with lower fees (management fee down 34% to R4.5m), holdco costs could fall below R35m.
-
Optionality in diagnostics and dialysis. RazoHealth (R40.8m) and Renal Healthcare Africa (R21.9m) are both still being revalued upward. A disclosed 15-centre radiology rollout and a dialysis JV with a specialist partner give organic growth that does not require large hospital capex.
Bear case
-
NAV is model-driven and has been revised down. All investments are Level-3 DCF valuations at WACCs of 19–21%. The FY2024 NAV jump rested largely on revaluing MMed from R1 to R158m within ten months. MMed, Ambit, Medicare and Fauchard were all written down in FY2026. Without third-party transactions, NAV credibility is low and the discount may be rational.
-
Minority shareholders have little leverage. The PIC owns 67%, the next holder 12%, and free float and liquidity are minimal. Costs (fees plus salaries via RHBM plus listing costs) absorb most cash income. "A" dividends have been paid in only two of nine years and none since December 2023.
-
Cash generation is weak and leverage has moved down into the portfolio. Holdco operating cash flow was negative in two of the last three years. The FY2026 dividend was largely non-cash: Norsad was "refinanced at asset level", so debt moved into Africa Healthcare rather than being extinguished. Net current assets have fallen to R10m.
Key catalysts and monitorables (next 12 months)
| Timing (expected) | Catalyst / monitorable |
|---|---|
| Late Nov 2026 (based on prior pattern) | H1 FY2027 interim results: NAV trend, cash dividends from RHBO, any further write-downs at MMed or Ambit, Capitec facility status |
| Unscheduled | Constitutional Court NHI judgment (reserved since 7 May 2026) and any subsequent promulgation timetable |
| Ongoing | RazoHealth practice count against the referenced 15-centre plan; Renal Healthcare Africa performance |
| Ongoing | Any asset realisation at or near NAV (e.g. property sale, partial disposal) — the strongest test of carrying values |
| Ongoing | Africa Healthcare's new asset-level debt: terms, covenants and impact on its valuation and dividend capacity (not disclosed in the retrieved sections) |
| Ongoing | Possible capital-allocation action to address the discount: dividend resumption, buyback, or a strategic transaction led by the PIC. None has been announced; this is analyst speculation, not a rumour. |
| May 2027 | FY2027 results and whether NAV growth clears the 10% "B" share hurdle |
Concluding analyst verdict
RH Bophelo is best understood as a sub-scale, externally managed South African healthcare private-equity portfolio wrapped in a listed shell. On paper it is solid: R1.10bn of NAV, a holding company that is now effectively debt-free, clean audit opinions, Level-1 B-BBEE status, and a portfolio that spans hospitals, pharmaceutical distribution, radiology, dialysis and pathology. The anchor asset, Africa Healthcare, produces real cash income.
The market price tells a different story. At about R1.65 against reported NAV of R16.96, investors are valuing the company at roughly a tenth of its stated worth. The evidence in the filings explains much of that scepticism:
-
Reported earnings depend on unrealised Level-3 revaluations made at 19–21% discount rates.
-
The FY2024 NAV surge rested heavily on revaluing a business bought for R1, and that value was partly reversed two years later.
-
FY2026's apparent tripling of dividend income was mostly a non-cash transfer that moved holding-company debt down into the hospital portfolio.
-
Per-share NAV has compounded at under 5% a year since FY2021.
-
The holding company's running costs consume most of its cash income.
-
Two-thirds of the shares sit with the PIC, so minorities depend on a single state-owned shareholder for any catalyst.
The risk/reward is therefore binary rather than incremental. If a credible third-party transaction, partial realisation, or PIC-led corporate action validated even half of reported NAV, the upside per share would be several-fold. Without such an event, the discount can persist indefinitely. Meanwhile the NHI judgment, elective-procedure weakness and continued write-downs in the asset-light ventures could erode NAV further.
For institutional readers the stock is not investable on liquidity grounds alone. For special-situations or strategic investors, the key diligence questions are:
-
the terms of the new Africa Healthcare debt;
-
look-through EBITDA and cash conversion of the top five assets;
-
the PIC's long-term intentions.
Our overall assessment is "deep value, low conviction". Fundamental asset backing appears real but unproven, and governance and structure, not operations, are the binding constraints on value realisation.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background (as disclosed) | FY2026 total remuneration (ZAR) |
|---|---|---|---|---|
Quinton Zunga | Founder, CEO and executive director | Since incorporation (Dec 2016) | Born in Zimbabwe's Eastern Highlands. About 16 years in investment banking (including Barclays) and about 4 years in private equity at listing. Earlier advisory work for Busamed. Majority shareholder of RQ Capital Partners. Director of RHBM and RH Managers. Education and age not publicly disclosed. | 3,048,979 (salary 2,725,401; bonus 323,578) |
Yondie Metu ("AY Metu") | CFO and executive director | Since 1 Dec 2023 | CA(SA). Prior roles, age and education beyond CA(SA) not publicly disclosed. | 3,048,979 (salary 2,725,401; bonus 323,578) |
Colin W. Clarke | Chief Investment Officer and executive director | Executive since at least FY2021 (earlier as non-executive per 2018 SENS) | Director of RHBM. Cross-directorships across most investees. Education and age not publicly disclosed. | 2,849,280 (salary 2,544,000; bonus 305,280) |
Directors' Remuneration
| Name | Classification | Appointed / tenure | Committees / notes | FY2026 fees (ZAR) |
|---|---|---|---|---|
Samson Moraba | Independent non-executive Chairman | Chairman since 11 Aug 2023; director before that | BCom, PMD. Left the ARC on 22 Aug 2025. | 729,000 |
Dr Phetole David Sekete | Non-executive (not independent) | Since at least 2018 | Medical doctor. A secondary source reports 33 years of medical experience. Cross-director of RHBO, Africa Healthcare and RH Managers. | 453,000 |
Fulufhelo Makwetla | Non-executive (not independent) | Since at least 2018 | Investment Committee member; director of RHBM | 496,000 |
Romeo Makhubela | Independent non-executive | 11 Aug 2023 | ARC member. BCom, MFin, MPhil. | 728,250 |
Carmen Mpelwane | Independent non-executive | 17 Jan 2025 | ARC chair from 15 Oct 2025. CA(SA), CFA. A secondary source describes her as a listed-equity portfolio manager with healthcare coverage. | 494,750 |
Thanyani Mashau | Independent non-executive | 17 Jan 2025 | Committees not disclosed in the sources retrieved | 406,500 |
Nontobeko S. Ndhlazi | Independent non-executive | 15 Oct 2025 | ARC member. BCom, PDip. | 189,750 |
Quinton Zunga | Executive (CEO) | 2016 | — | — |
Yondie Metu | Executive (CFO) | 2023 | — | — |
Colin Clarke | Executive (CIO) | — | — | — |
Bojane Segooa (former) | Independent non-executive; former ARC chair | Resigned 21 Aug 2025 | CA(SA), MCom | 175,000 |
Major Shareholders
| Shareholder | Stake | As at | Source |
|---|---|---|---|
Public Investment Corporation SOC Ltd | 67.00% | 28 Feb 2025 | Profile's Stock Exchange Handbook 2025 |
Perthpark Properties | 12.00% | 28 Feb 2025 | Profile's Handbook (PitchBook lists Perthpark as a former Rondebosch Medical Centre investor, consistent with shares issued for RMC in 2020) |
"Dr Mandisa Joyce Gwendoline" (name as printed; possibly truncated) | 3.00% | 28 Feb 2025 | Profile's Handbook |
RQ Capital Partners (Pty) Ltd (CEO majority-owned) | about 3% | FY2025 | FY2025 AFS, note 21 |
Other holders | about 15% | — | Residual (analyst-derived) |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Ownership | Relevance |
|---|---|---|---|
Acute hospitals | Netcare Ltd | JSE-listed | Largest private hospital group; national footprint |
Acute hospitals | Life Healthcare Group | JSE-listed | Second-largest listed hospital group; also in renal care |
Acute hospitals | Mediclinic Southern Africa | Private (Mediclinic taken private in 2023 per general market knowledge; current financials not publicly comparable) | Major competitor, including Mediclinic Welkom near St Helena |
Acute hospitals | Lenmed Health | Private | Independent hospital group targeting similar peri-urban markets |
Acute hospitals | Clinix Health Group | Private | Township/peri-urban private hospitals; direct overlap with RH Bophelo's affordable-care thesis |
Acute hospitals | Busamed | Private | Independent group; the CEO previously advised it |
Acute hospitals (Western Cape) | Melomed Hospital Holdings | Private | Cape Town independent group; competes with Rondebosch Medical Centre |
Pharmaceutical distribution | United Pharmaceutical Distributors (Clicks Group) | JSE-listed parent | Leading full-line pharma wholesaler; competes with MMed/1-Pharma |
Pharmaceutical distribution | Dis-Chem (wholesale arm) | JSE-listed | Pharmacy retail and wholesale |
Pathology | Lancet Laboratories, Ampath, PathCare | Private | The three dominant private pathology groups; compete with Ambit/Pelo |
Dialysis | National Renal Care; Life Healthcare renal (incl. the former Fresenius SA assets referenced in Life's FY2025 interims) | Private / JSE-listed | Compete with Renal Healthcare Africa |
Benefits administration | Discovery Health, Medscheme (AfroCentric) | Listed / private | Dominant administrators (HMI: 76% of administrator market by GCI); compete with Wesmart |
Peer Comparison FY2026
| Metric | RH Bophelo (FY2026, y/e Feb 2026) | Netcare (FY2025, y/e Sep 2025) | Life Healthcare (FY2025, y/e Sep 2025) |
|---|---|---|---|
Revenue / revenue proxy (ZAR Mn) | 53.4 (total income, company-only) | 26,344 | 25,100 (continuing operations) |
Revenue growth (%) | -52.3 | 4.5 | 6.0 |
EBITDA (ZAR Mn) | 27.3 (analyst-derived, company-only) | 4,912 (normalised) | 3,800 (normalised) |
EBITDA margin (%) | 51.0 (on investment income; not comparable) | 18.6 | about 15 (analyst-derived) |
Net debt / EBITDA (x) | -0.08 (holdco) | 1.1 (excluding IFRS 16) | — |
Recent Developments
Not observed in the period: layoffs or hiring announcements, litigation, regulatory sanctions, guidance revisions or new acquisitions. H1 FY2027 interim results (to 31 August 2026) had not been published* as at 14 October 2026.



